EMA-CAT Evaluation of ATMPs: From Classification to Approval EMA-CAT Evaluation of ATMPs: From Classification to Approval The Advanced Therapy Medicinal Products (ATMPs) represent a significant innovation within the pharmaceutical world, encompassing gene therapy, somatic cell therapy, and tissue-engineered products. For companies looking to navigate the regulatory landscape, understanding the European Medicines Agency’s Committee for Advanced Therapies (EMA-CAT) evaluation process is crucial. This guide provides a comprehensive, step-by-step walkthrough from classification to approval of ATMPs, ensuring compliance with relevant regulations. Step 1: Understanding ATMP Regulations and Classification Before commencing the development of an ATMP, it is essential to familiarize yourself with…

EMA Variations vs FDA Supplements: Change Strategy for US–EU Lifecycle Management EMA Variations vs FDA Supplements: Change Strategy for US–EU Lifecycle Management Step 1: Understand the Regulatory Framework for Variations and Supplements Before engaging in the management of drug lifecycle changes, it is essential to establish a firm understanding of the regulatory frameworks governing EMA variations and FDA supplements. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) provide distinct pathways for modifying existing marketing authorizations. Compliance with these frameworks is crucial for maintaining compliance and ensuring patient safety. The EMA classifies variations into three categories:…

CMDh Referral Outcomes: Risk Mitigation Tips for US-Based MA Holders in 2023 CMDh Referral Outcomes: Risk Mitigation Tips for US-Based MA Holders in 2023 In the ever-evolving landscape of pharmaceutical regulation, understanding the implications of CMDh referrals and the related EMA-CAT processes is crucial for maintaining regulatory compliance and ensuring the ongoing success of marketing authorizations (MAs) in the European Union. While this article is particularly relevant for US-based MA holders, the methodologies described herein are applicable to other stakeholders involved in global drug development and distribution. This comprehensive guide will walk you through the critical steps of navigating CMDh…

EMA-CAT ATMP Classification: What US Sponsors Should Prepare Before EU Advice EMA-CAT ATMP Classification: What US Sponsors Should Prepare Before EU Advice The process of navigating the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) in the European Union (EU) requires meticulous planning and an understanding of both regulatory strategies and documentation requirements. This article aims to provide a comprehensive, step-by-step guide for US sponsors on the preparations needed before seeking advice from the European Medicines Agency’s Committee for Advanced Therapies (EMA-CAT) regarding ATMP classification. Step 1: Understand the ATMP Classification Framework Before initiating your application for EU advice, it’s…

EU MAA via CMDh Coordination: Document Set Checklist for US Regulatory Teams EU MAA via CMDh Coordination: Document Set Checklist for US Regulatory Teams The submission and approval of a Marketing Authorisation Application (MAA) within the European Union (EU) can be a complex process. For US regulatory teams, understanding the Coordination Group for Mutual Recognition and Decentralised Procedures – human (CMDh) is essential for ensuring compliance in cross-border pharmaceutical regulations. This guide presents a step-by-step tutorial to navigate the intricacies of the EU MAA via CMDh coordination, providing a comprehensive document set checklist tailored for US pharmaceutical professionals. Step 1:…

EMA-CAT Quality Dossier Hotspots: CMC Issues That Delay ATMP Approvals in 2023 EMA-CAT Quality Dossier Hotspots: CMC Issues That Delay ATMP Approvals in 2023 The development and approval of Advanced Therapy Medicinal Products (ATMPs) require meticulous compliance with regulatory expectations, particularly in the context of manufacturing and quality. Understanding the intricacies of the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) expectations is critical for achieving timely approvals. This article presents a step-by-step tutorial on navigating common Chemistry, Manufacturing and Controls (CMC) issues that frequently cause delays in authorization processes through the Marketing Authorization Application (MAA) for ATMPs, focusing…